120 related articles for article (PubMed ID: 21510948)
1. Orexin/hypocretin receptor chimaeras reveal structural features important for orexin peptide distinction.
Putula J; Turunen PM; Johansson L; Näsman J; Ra R; Korhonen L; Kukkonen JP
FEBS Lett; 2011 May; 585(9):1368-74. PubMed ID: 21510948
[TBL] [Abstract][Full Text] [Related]
2. Mapping of the binding sites for the OX1 orexin receptor antagonist, SB-334867, using orexin/hypocretin receptor chimaeras.
Putula J; Kukkonen JP
Neurosci Lett; 2012 Jan; 506(1):111-5. PubMed ID: 22079339
[TBL] [Abstract][Full Text] [Related]
3. Orexin-A is composed of a highly conserved C-terminal and a specific, hydrophilic N-terminal region, revealing the structural basis of specific recognition by the orexin-1 receptor.
Takai T; Takaya T; Nakano M; Akutsu H; Nakagawa A; Aimoto S; Nagai K; Ikegami T
J Pept Sci; 2006 Jul; 12(7):443-54. PubMed ID: 16429482
[TBL] [Abstract][Full Text] [Related]
4. Structural properties of orexins for activation of their receptors.
Lang M; Bufe B; De Pol S; Reiser O; Meyerhof W; Beck-Sickinger AG
J Pept Sci; 2006 Apr; 12(4):258-66. PubMed ID: 16138386
[TBL] [Abstract][Full Text] [Related]
5. Agonist ligand discrimination by the two orexin receptors depends on the expression system.
Putula J; Turunen PM; Jäntti MH; Ekholm ME; Kukkonen JP
Neurosci Lett; 2011 Apr; 494(1):57-60. PubMed ID: 21362456
[TBL] [Abstract][Full Text] [Related]
6. Distinct recognition of OX1 and OX2 receptors by orexin peptides.
Ammoun S; Holmqvist T; Shariatmadari R; Oonk HB; Detheux M; Parmentier M; Akerman KE; Kukkonen JP
J Pharmacol Exp Ther; 2003 May; 305(2):507-14. PubMed ID: 12606634
[TBL] [Abstract][Full Text] [Related]
7. NMR conformational studies of micelle-bound orexin-B: a neuropeptide involved in the sleep/awake cycle and feeding regulation.
Miskolzie M; Lucyk S; Kotovych G
J Biomol Struct Dyn; 2003 Dec; 21(3):341-51. PubMed ID: 14616030
[TBL] [Abstract][Full Text] [Related]
8. Study of human Orexin-1 and -2 G-protein-coupled receptors with novel and published antagonists by modeling, molecular dynamics simulations, and site-directed mutagenesis.
Heifetz A; Morris GB; Biggin PC; Barker O; Fryatt T; Bentley J; Hallett D; Manikowski D; Pal S; Reifegerste R; Slack M; Law R
Biochemistry; 2012 Apr; 51(15):3178-97. PubMed ID: 22448975
[TBL] [Abstract][Full Text] [Related]
9. Mapping the binding pocket of dual antagonist almorexant to human orexin 1 and orexin 2 receptors: comparison with the selective OX1 antagonist SB-674042 and the selective OX2 antagonist N-ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-N-pyridin-3-ylmethyl-acetamide (EMPA).
Malherbe P; Roche O; Marcuz A; Kratzeisen C; Wettstein JG; Bissantz C
Mol Pharmacol; 2010 Jul; 78(1):81-93. PubMed ID: 20404073
[TBL] [Abstract][Full Text] [Related]
10. Chimeric, mutant orexin receptors show key interactions between orexin receptors, peptides and antagonists.
Tran DT; Bonaventure P; Hack M; Mirzadegan T; Dvorak C; Letavic M; Carruthers N; Lovenberg T; Sutton SW
Eur J Pharmacol; 2011 Sep; 667(1-3):120-8. PubMed ID: 21679703
[TBL] [Abstract][Full Text] [Related]
11. Intramolecular fluorescence resonance energy transfer (FRET) sensors of the orexin OX1 and OX2 receptors identify slow kinetics of agonist activation.
Xu TR; Ward RJ; Pediani JD; Milligan G
J Biol Chem; 2012 Apr; 287(18):14937-49. PubMed ID: 22389503
[TBL] [Abstract][Full Text] [Related]
12. The hypocretins are weak agonists at recombinant human orexin-1 and orexin-2 receptors.
Smart D; Jerman JC; Brough SJ; Neville WA; Jewitt F; Porter RA
Br J Pharmacol; 2000 Apr; 129(7):1289-91. PubMed ID: 10742282
[TBL] [Abstract][Full Text] [Related]
13. The NMR-derived conformation of orexin-A: an orphan G-protein coupled receptor agonist involved in appetite regulation and sleep.
Miskolzie M; Kotovych G
J Biomol Struct Dyn; 2003 Oct; 21(2):201-10. PubMed ID: 12956605
[TBL] [Abstract][Full Text] [Related]
14. The orexin OX(1) receptor exists predominantly as a homodimer in the basal state: potential regulation of receptor organization by both agonist and antagonist ligands.
Xu TR; Ward RJ; Pediani JD; Milligan G
Biochem J; 2011 Oct; 439(1):171-83. PubMed ID: 21770891
[TBL] [Abstract][Full Text] [Related]
15. Development of an orexin-2 receptor selective agonist, [Ala(11), D-Leu(15)]orexin-B.
Asahi S; Egashira S; Matsuda M; Iwaasa H; Kanatani A; Ohkubo M; Ihara M; Morishima H
Bioorg Med Chem Lett; 2003 Jan; 13(1):111-3. PubMed ID: 12467628
[TBL] [Abstract][Full Text] [Related]
16. Orexin B/hypocretin 2 increases glutamatergic transmission to ventral tegmental area neurons.
Borgland SL; Storm E; Bonci A
Eur J Neurosci; 2008 Oct; 28(8):1545-56. PubMed ID: 18793323
[TBL] [Abstract][Full Text] [Related]
17. The signalling profile of recombinant human orexin-2 receptor.
Tang J; Chen J; Ramanjaneya M; Punn A; Conner AC; Randeva HS
Cell Signal; 2008 Sep; 20(9):1651-61. PubMed ID: 18599270
[TBL] [Abstract][Full Text] [Related]
18. A role for PKD1 and PKD3 activation in modulation of calcium oscillations induced by orexin receptor 1 stimulation.
Peltonen HM; Akerman KE; Bart G
Biochim Biophys Acta; 2010 Oct; 1803(10):1206-12. PubMed ID: 20621130
[TBL] [Abstract][Full Text] [Related]
19. Orexins promote survival of rat cortical neurons.
Sokołowska P; Urbańska A; Namiecińska M; Biegańska K; Zawilska JB
Neurosci Lett; 2012 Jan; 506(2):303-6. PubMed ID: 22138089
[TBL] [Abstract][Full Text] [Related]
20. Involvement of TRPC3 channels in calcium oscillations mediated by OX(1) orexin receptors.
Peltonen HM; Magga JM; Bart G; Turunen PM; Antikainen MS; Kukkonen JP; Akerman KE
Biochem Biophys Res Commun; 2009 Jul; 385(3):408-12. PubMed ID: 19464259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
